Search

Displaying results 1271 - 1280 of 2482 in total
  1. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth hormone (GH) and decreases the pro...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  2. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, whi...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  3. Drug

    Azasetron

    go.drugbank.com/drugs/DB16837
    Investigational

    Categories: P-glycoprotein substrates
  4. Drug

    Naringin

    go.drugbank.com/drugs/DB16859
    Experimental

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  5. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  6. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    Imlunestrant is a brain-penetrant selective estrogen receptor antagonist and degrader. The FDA approved imlunestrant on September 25, 2025 as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-muta...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Benzgalantamine

    go.drugbank.com/drugs/DB19353
    ApprovedInvestigational

    Benzgalantamine is a prodrug of galantamine. Gastrointestinal adverse effects are the most frequently reported side effects in patients undergoing treatment with cholinesterase inhibitors, including galantamine, and are often a reason fo...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  8. Drug

    Hydrastine

    go.drugbank.com/drugs/DB19354
    Experimental

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Setileuton

    go.drugbank.com/drugs/DB19550
    Investigational

    Setileuton is a small molecule drug. The usage of the INN stem '-leuton' in the name indicates that Setileuton is a 5-lipo-oxygenase inhibitor, anti-inflammatory. Setileuton is under investigation in clinical trial NCT00404313 (The Effec...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    Mifentidine

    go.drugbank.com/drugs/DB19721
    Experimental

    Mifentidine is a small molecule drug. The usage of the INN stem '-tidine' in the name indicates that Mifentidine is a histamine- H2​-receptor antagonist, cimetidine derivative. Mifentidine has a monoisotopic molecular weight of 228.14 Da.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors